How should hypoglycemia be managed in a patient receiving treatment for diabetic ketoacidosis without stopping the insulin infusion?

Management of Hypoglycemia During DKA Treatment

When hypoglycemia occurs during DKA treatment, immediately administer intravenous dextrose while continuing the insulin infusion at the same rate—never stop or reduce the insulin, as this will cause recurrent ketoacidosis.

Immediate Hypoglycemia Management

• Administer 10–20 g of IV dextrose (20–50 mL of 50% dextrose or 100–200 mL of 10% dextrose) titrated to raise blood glucose above 70 mg/dL, then recheck glucose after 15 minutes and repeat as needed 1
• Alternatively, give 10% dextrose in 50-mL (5-g) IV aliquots, repeating every minute until symptoms resolve; avoid 50% dextrose because it causes over-correction and rebound hyperglycemia 1
• Never discontinue or reduce the insulin infusion when hypoglycemia occurs—insulin must continue to clear ketones and prevent recurrent DKA 1, 2

Transition to Dextrose-Containing Fluids

• When plasma glucose falls to 250 mg/dL (or immediately if hypoglycemia develops), switch IV fluids to 5% dextrose with 0.45–0.75% saline while maintaining the same insulin infusion rate 1, 2
• This dextrose addition allows continued insulin therapy to clear ketones while preventing further hypoglycemia 1, 2
• In euglycemic DKA (initial glucose <250 mg/dL), start dextrose-containing fluids from the outset of insulin therapy 2

Insulin Infusion Continuation

• Continue insulin at 4–6 U/h or higher (with appropriate glucose supplementation) until complete resolution of ketoacidosis, even if this requires high-dose insulin for several days 3
• The insulin infusion must run until all resolution criteria are met: pH >7.3, bicarbonate ≥18 mEq/L, anion gap ≤12 mEq/L, and β-hydroxybutyrate <1.0 mmol/L 1, 2
• Premature termination of insulin is the most common cause of recurrent DKA—glucose normalization alone does not indicate ketoacidosis resolution 1, 4

Monitoring Protocol During Hypoglycemia Management

• Check capillary or venous blood glucose every 1–2 hours during active insulin infusion, extending to every 2–4 hours once stable 1, 2
• Measure serum electrolytes (especially potassium), venous pH, bicarbonate, and anion gap every 2–4 hours until metabolic stability 1, 2
• Check serum potassium before each insulin adjustment because insulin drives potassium intracellularly; severe hypokalemia (<2.5 mEq/L) increases mortality 1

Potassium Management During Hypoglycemia Correction

• Maintain serum potassium 4.0–5.0 mEq/L throughout DKA treatment by adding 20–30 mEq/L potassium to IV fluids (using 2/3 KCl or potassium acetate and 1/3 KPO₄) 1, 2
• Monitor potassium every 2–4 hours because insulin-mediated intracellular shift causes rapid declines even with total body depletion 1, 2

Carbohydrate Provision in Euglycemic DKA

• If the patient has concurrent gastrointestinal symptoms limiting oral intake, provide 150–200 g of carbohydrate per day (approximately 45–50 g every 3–4 hours) through liquid sources (juice, broth, sports drinks) to suppress starvation ketosis 2
• Do not withhold carbohydrate once oral feeding begins—insulin alone cannot clear ketones without adequate glucose substrate 2

Critical Pitfalls to Avoid

• Stopping insulin when glucose normalizes is the single most common error leading to recurrent ketoacidosis—add dextrose instead 1, 2, 4
• Inadequate glucose monitoring (checking every 4 hours instead of 1–2 hours) is linked to hypoglycemia rates >10% 1
• Failure to add dextrose at 250 mg/dL while continuing insulin leads to hypoglycemia and potential insulin discontinuation 1, 2
• Premature transition to subcutaneous insulin before complete ketoacidosis resolution (all criteria met simultaneously) causes DKA recurrence 1, 2

Transition to Subcutaneous Insulin

• Administer long-acting basal insulin (glargine or detemir) 2–4 hours before stopping the IV insulin infusion to prevent rebound hyperglycemia and recurrent DKA 1, 2
• Continue the IV insulin infusion for an additional 1–2 hours after the subcutaneous basal dose to ensure adequate absorption 1, 2
• Use approximately 50% of the total 24-hour IV insulin dose as the daily basal insulin, with the remaining 50% divided among three meals as rapid-acting prandial insulin 1, 2